A Delphi Study of Core Patient-Reported Outcomes for Advanced Renal Cell Carcinoma and Advanced Hepatocellular Carcinoma

被引:1
|
作者
de la Serna, Celia Diez de los Rios [1 ]
Drury, Amanda [2 ]
Oldenmenger, Wendy H. [3 ]
Kelly, Daniel [4 ]
Kotronoulas, Grigorios [5 ]
机构
[1] European Oncol Nursing Soc EONS, Oncol Adv Nurse Practitioner, Brussels, Belgium
[2] Dublin City Univ, Sch Nursing Psychotherapy & Community Hlth, Dublin, Ireland
[3] Univ Med Ctr, Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Cardiff Univ, Sch Healthcare Sci, Cardiff, Wales
[5] Univ Glasgow, Sch Med Dent & Nursing, Glasgow City, Scotland
关键词
Patient-reported outcomes; Advanced renal cell carcinoma; Cancer; Advanced hepatocellular carcinoma; Quality of life; Person-centered care; QUALITY-OF-LIFE; CANCER; PROS; CARE;
D O I
10.1016/j.soncn.2023.151409
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: There is little research to help health care professionals understand what patient outcomes are considered a priority in advanced liver or kidney cancer. Knowing what is important to patients can help pro-mote person-centered approaches to treatment and disease management. The aim of this study was to identify those patient-reported outcomes (PROs) that patients, carers, and health care professionals consider as "core" when providing care to those with advanced liver or kidney cancer.Data sources: A three-round Delphi study was undertaken to ask experts by profession or experience to rank PROs identified from a previous literature review. Fifty-four experts, including people living with advanced liver or kidney cancer (44.4%), family members and caregivers (9.3%), and health care professionals (46.8%), reached consensus on 49 PROs including 12 new items (eg, palpitations, hopefulness, or social isolation). Items with the highest rate of consensus included quality of life, pain, mental health, and capacity to do daily activities.Conclusion: People living with advanced liver or kidney cancer experience complex health care needs. Some important outcomes were not actually captured in practice in this population and were suggested as part of this study. There are discrepancies between the views of health care professionals, patients, and family in what is important, highlighting the need of using measures to facilitate communication. Implications for Nursing Practice: Identification of priority PROs reported here will be key to facilitate more focused patient assessments. The actual use of measures in cancer nursing practice to allow monitoring of PROs must be tested for feasibility and usability.& COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Recurrent hypoglycemia in a patient with advanced Hepatocellular Carcinoma
    Chouhan, Balpreet
    JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2024, 14 (06):
  • [32] Rapidly progressive glomerulonephritis in a patient with advanced renal cell carcinoma
    Sommer, M
    Schmidt, R
    Lambrecht, E
    Fink, H
    Geiger, H
    Lenz, T
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (08) : 2107 - 2109
  • [33] Patient-reported impairment of EuroQol health states and preference-weighted utility in advanced renal cell carcinoma in a recent clinical trial
    Mallick, R.
    Sun, S.
    Hudes, G.
    VALUE IN HEALTH, 2007, 10 (06) : A344 - A344
  • [34] Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
    Choueiri, Toni K.
    Tomczak, Piotr
    Park, Se Hoon
    Venugopal, Balaji
    Symeonides, Stefan
    Hajek, Jaroslav
    Ferguson, Thomas
    Chang, Yen-Hwa
    Lee, Jae Lyun
    Haas, Naomi
    Sawrycki, Piotr
    Sarwar, Naveed
    Gross-Goupil, Marine
    Thiery-Vuillemin, Antoine
    Mahave, Mauricio
    Kimura, Go
    Perini, Rodolfo F.
    Saretsky, Todd L.
    Bhattacharya, Rituparna
    Xu, Lei
    Powles, Thomas
    ONCOLOGIST, 2024, 29 (02): : 142 - 150
  • [35] Pazopanib In Advanced Renal Cell Carcinoma
    Sanford, Mark
    Keating, Gillian M.
    BIODRUGS, 2010, 24 (05) : 279 - 286
  • [36] Locally advanced renal cell carcinoma
    Al Otaibi, Mohammed
    Tanguay, Simon
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2007, 1 (02): : S55 - S61
  • [37] Imaging of advanced renal cell carcinoma
    Mueller-Lisse, Ullrich G.
    Mueller-Lisse, Ulrike L.
    WORLD JOURNAL OF UROLOGY, 2010, 28 (03) : 253 - 261
  • [38] Temsirolimus for advanced renal cell carcinoma
    Bergmann, Lothar
    Maute, Luise
    Guschmann, Michael
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (01) : 9 - 21
  • [39] Management of advanced renal cell carcinoma
    Northway, RO
    Ritenour, CWM
    Marshall, FF
    RENAL, BLADDER, PROSTATE AND TESTICULAR CANCER: AN UPDATE, 2001, : 75 - 78
  • [40] Advanced renal cell carcinoma.
    Redman B.G.
    Chang A.E.
    Current Treatment Options in Oncology, 2000, 1 (5) : 417 - 422